Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 17/20 | 0.50 |
| ▸ | RARG | P13631 | 17/20 | 0.50 |
| ▸ | RARA | P10276 | 13/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 2/20 | 0.39 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5735587 | 0.84 | RARB (0.52) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL5736750 | 0.79 | RARB (0.54) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL5736240 | 0.78 | RARB (0.53) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL5736646 | 0.76 | RARB (0.41) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL5735737 | 0.74 | RARB (0.51) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL7132529 | 0.74 | RARB (0.48) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL7970579 | 0.73 | RARB (0.37) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL5737550 | 0.72 | FFAR1 (0.43) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL5735777 | 0.71 | RARA (0.43) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL6426294 | 0.71 | RARB (0.37) | RARBRARGRARACYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030078270-A1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078270-A1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | CYP26B1, CYP21A2, ALDH1A2 | RARB 14/4885RARG 15/4885RARA 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.